BioClinica Celebrates 10th Consecutive Year as a Deloitte Fast 50 Company

-Clinical Trials Solution Provider Attributes 87 Percent, Four-Year Total Revenue Increase to Solid Growth Strategy and Continued Employee Commitment-

NEWTOWN, Pa.--(BUSINESS WIRE)-- BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced it ranked 30 on Deloitte’s 2011 Greater Philadelphia Fast 50 ranking of the 50 fastest growing technology, media, telecommunications, life sciences and clean technology companies in the Greater Philadelphia region. This is the tenth year in a row that BioClinica has been recognized as one of the region’s top companies.

BioClinica’s chief executive officer, Mark Weinstein, credits a solid growth strategy and unparalleled customer-focused technologies and services with the company’s 87 percent, four-year total revenue growth.

“We are proud to be recognized by Deloitte as a leading company in the Philadelphia area for the tenth year in a row,” said Mr. Weinstein. “BioClinica’s growth strategy has brought great success to both us and our clients. Our entire team works incredibly hard every day to provide the industry’s best service to the various sponsors and CROs we support. Our customer partnerships are why BioClinica is an industry leader. This recognition is a testament to our employees’ continued commitment to excellence.”

“BioClinica, like all 2011 Greater Philadelphia Fast 50 companies, has excelled in fostering innovation and channeling it into spectacular growth -- against the backdrop of one of the most challenging economies in history,” said Tara L. Weiner, managing partner, Greater Philadelphia region, Deloitte LLP. “Deloitte recognizes BioClinica for its remarkable accomplishment.”

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About Deloitte’s 2011 Greater Philadelphia Fast 50

The 2011 Greater Philadelphia Fast 50, which was conducted by Deloitte & Touche LLP, a subsidiary of Deloitte LLP, provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies – both public and private - in the Greater Philadelphia region. 2011 Greater Philadelphia Fast 50 award winners are selected based on percentage fiscal year revenue growth from 2006 to 2010. In order to be eligible for 2011 Greater Philadelphia Fast 50 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least $50,000 USD, and current-year operating revenues of at least $5 million USD. Additionally, companies must be in business for a minimum of five years, and be headquartered within the Greater Philadelphia region.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.



CONTACT:

BioClinica, Inc.
Jim Dorsey, 267-757-3040
or
Diccicco Battista Communications
Trade Media - Rachel Summers
484-342-3600
or
Porter, LeVay & Rose, Inc.
Investors - Michael Porter
Financial Media - Bill Gordon
212-564-4700

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Technology  Data Management  Software  Health  Biotechnology  Clinical Trials  Other Health  General Health

MEDIA:

Logo
 Logo

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.